Company: Beijing Tiantan Biological Products Corporation Limited
Bloomberg ticker: 600161 SH
Market cap: US$5,742m
Background: Beijing Tiantan Biological Products Corporation Limited researches, develops, and commercializes biological products. The Company provides treatment for hepatitis and offers a line of vaccine products including hepatitis vaccines and rubella vaccines.
World Class Benchmarking of Beijing Tiantan Biological Products Corp
- Profitable Growth rank of 3 was up compared to the prior period’s 5th rank
- This is above average performance compared to 380 large Health Care companies worldwide
- Profitability rank of 4 was worse than its Growth rank of 2
- Profitability rank of 4 was the same compared to the prior period’s 4th rank
- This is above average performance compared to peers
- Growth rank of 2 was up compared to the prior period’s 5th rank
- This is World Class performance compared to peers
DISCLAIMER: This content is for information purposes only. It is not intended to be investment advice. Readers should not consider statements made by the author(s) as formal recommendations and should consult their financial advisor before making any investment decisions. While the information provided is believed to be accurate, it may include errors or inaccuracies. The author(s) cannot be held liable for any actions taken as a result of reading this article.